Virtual Library
Start Your Search
J. Terrasa
Author of
-
+
P3.04 - Poster Session/ Biology, Pathology, and Molecular Testing (ID 235)
- Event: WCLC 2015
- Type: Poster
- Track: Biology, Pathology, and Molecular Testing
- Presentations: 1
- Moderators:
- Coordinates: 9/09/2015, 09:30 - 17:00, Exhibit Hall (Hall B+C)
-
+
P3.04-046 - Prevalence of ROS1, HER2, and BRAF Alterations in a Cohort of Advanced Non-Small Cell Lung Cancer (NSCLC) Patients (P) Triple Negative (TN) (ID 2711)
09:30 - 09:30 | Author(s): J. Terrasa
- Abstract
Background:
During the last years, new predictive and less frequent biomarkers have emerged in NSCLC, such as ROS1 translocation (ROS1t), HER2 mutations (HER2m) and BRAF mutations (BRAFm). We analyze retrospectively the frequency, clinical and tumor characteristics of NSCLC p TN( EGFR, KRAS and ALK wild-type).
Methods:
The study included data from all consecutive non-squamous and non-smokers squamous TN advanced NSCLC p diagnosed at our hospital from December 2008 to July 2014
Results:
101 p were included. The table below summarizes p characteristics. ROS1t were found in 4.9% p and were found more in female gender (100%), non-smokers(100%), stage IV (100%), adenocarcinoma histology (100%) and p had more lung metastasis(50% vs 34.2%), brain metastasis (50%vs 38.5%) and pleural/pericardial effusions (50% vs 12.8%). HER2m was found in 1 p (1.25%). Female, non-smoker and adenocarcinoma histology. BRAFm were found in 2 p ( 3.2%), one male and one female, smokers and adenocarcinoma histology. Valid results range from 85.6% to 96.2% for biopsy samples and from 78.2% to 81.4% for citology samples.TOTAL(N101) ROS1(N81) BRAF(N80) HER2(N80) Mean age 61 58 63 63 Gender Male Female 65(64,3%) 36(35,6%) 57(70,3%) 24(29,6%) 52 (65%) 28(35%) 52(65%) 28(35%) Smoking history Current Former Never 38(37,6%) 41(40,5%) 22(21,7%) 32(39,5%) 37(45,6%) 12(14,8%) 33(41,2%) 31(38,7%) 16(20%) 33(41,2%) 31(38,7%) 16(20%) Histology Adenocarcinoma Squamous NOS LCC 88(87,1%) 5(4,9%) 6(5,9%) 2(1,9%) 72(88,8%) 3(3,7%) 6(7,4%) 0 71(88,7%) 2(2,5%) 5(6,2%) 2(2,5%) 71(88,7%) 2(2,5%) 5(6,2%) 2(2,5%) Sample CItology Biopsy 29(28,7%) 72(71,2%) 27(33,3%) 54(66,6%) 23 (28,7%) 57 (71,2%) 23 (28,7%) 57 (71,2%) Site metastasis Lung Bone Brain Liver 33(32,6%) 28(27,7%) 30(29,7%) 9(8,9%) 28(34,5%) 21(25,9%) 25(30,8%) 5(6,1%) 25(31,2%) 22(27,5%) 27(33,7%) 7(8,7%) 25(31,2%) 22(27,5%) 27(33,7%) 7(8,7%)
Conclusion:
ROS1t, HER2m and BRAFm have emerged as targetable oncogenic drivers in NSCLC. Although the prevalence is low (1%–2%), could be increased selecting by clinical and molecular characteristics. Citology samples could be useful to detect these molecular alterations.
